441 related articles for article (PubMed ID: 19929170)
21. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
[TBL] [Abstract][Full Text] [Related]
22. The great escape: viral strategies to counter BST-2/tetherin.
Douglas JL; Gustin JK; Viswanathan K; Mansouri M; Moses AV; Früh K
PLoS Pathog; 2010 May; 6(5):e1000913. PubMed ID: 20485522
[TBL] [Abstract][Full Text] [Related]
23. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
25. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
[TBL] [Abstract][Full Text] [Related]
26. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
27. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
[TBL] [Abstract][Full Text] [Related]
28. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
29. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
30. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
[TBL] [Abstract][Full Text] [Related]
31. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
32. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
33. Tetherin/BST-2: Restriction Factor or Immunomodulator?
Li SX; Barrett BS; Guo K; Santiago ML
Curr HIV Res; 2016; 14(3):235-46. PubMed ID: 26957198
[TBL] [Abstract][Full Text] [Related]
34. Tetherin restricts direct cell-to-cell infection of HIV-1.
Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
[TBL] [Abstract][Full Text] [Related]
35. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
36. BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
Richard J; Prévost J; von Bredow B; Ding S; Brassard N; Medjahed H; Coutu M; Melillo B; Bibollet-Ruche F; Hahn BH; Kaufmann DE; Smith AB; Sodroski J; Sauter D; Kirchhoff F; Gee K; Neil SJ; Evans DT; Finzi A
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331088
[TBL] [Abstract][Full Text] [Related]
37. Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.
Bego MG; Cong L; Mack K; Kirchhoff F; Cohen ÉA
J Virol; 2016 Nov; 90(22):10236-10246. PubMed ID: 27581991
[TBL] [Abstract][Full Text] [Related]
38. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
39. Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.
Serra-Moreno R; Zimmermann K; Stern LJ; Evans DT
PLoS Pathog; 2013; 9(7):e1003487. PubMed ID: 23853598
[TBL] [Abstract][Full Text] [Related]
40. Plasma Membrane-Associated Restriction Factors and Their Counteraction by HIV-1 Accessory Proteins.
Ramirez PW; Sharma S; Singh R; Stoneham CA; Vollbrecht T; Guatelli J
Cells; 2019 Sep; 8(9):. PubMed ID: 31480747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]